Guardant Health Introduces Shield Blood Test for Colorectal Cancer in South Korea

13 November 2023 | Monday | News


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
Image Source : Public Domain

Image Source : Public Domain

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and the third-leading cause of cancer-related deaths in South Korea.1,2 Guardant Health's Shield test, which can be used for regular CRC screening in eligible individuals, is an innovative test that can detect cancer in its early stages by analysing circulating tumour DNA (ctDNA), which is produced when tumours shed small pieces of their genetic material into the bloodstream. In the pivotal ECLIPSE study, which enrolled over 20,000 patients, the Shield test achieved 83% sensitivity for the detection of colorectal cancer in average-risk adults in the U.S., with specificity of 90%.3

Early detection is essential to reduce colorectal cancer mortality. Colonoscopy and faecal tests are generally used for early detection, however, compliance rates for these screening tests are low and have remained stagnant since 2014.The primary reasons for lack of compliance with CRC screening recommendations include not having any symptoms of CRC, lack of time for a colonoscopy procedure, which requires a few days of preparation, and fear of an invasive colonoscopy procedure.4 Since the launch of the lab-developed version of the Shield test in May 2022, it has shown approximately 90% adherence in a real-world clinical setting, demonstrating the value of blood-based screening to increase adherence to recommended screening protocols.5

"Colorectal cancer rarely has symptoms in its early stages, and by the time symptoms appear, the disease has often progressed considerably. Therefore, early detection through a screening test is critical," said Health Promotion Center of Samsung Medical Center. "The Shield blood test can broaden the range of choices for colorectal cancer screening. We are confident that by introducing a high-quality blood-based screening test, we can meet the needs of both patients and healthcare providers and help improve screening compliance."

"We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa. "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close